Commercial transformation across European life sciences
Pharma, MedTech, Digital Health and AI.
Life Sciences Commercial Transformation in Europe: Strategy, Market Signals, and What Comes Next
Commercialization, regulation, AI, and operating-model shifts shaping pharma, MedTech, and digital health in Europe – from an operator’s perspective.
Weekly Life Sciences Signal
Weekly analysis of funding, regulation, AI, commercial moves, and execution signals shaping life sciences in Europe.
Europe Life Sciences Weekly Brief #41: The Premium on Certainty
Week of 8–14 June 2026 This was a week about the price of proof. GSK paid a premium for late-stage oncology assets already under FDA review. Roche put serious money behind a validated target through a newer modality. Europe’s medicines regulators made reliability the centre of the AI conversation. The UK edged closer to a…
Europe Life Sciences Weekly Signal #40: The Bottleneck Moves Downstream
Week of 1–7 June 2026 This was a week of things being declared ready. Merck arrived at ASCO with a clearer post-Keytruda oncology portfolio story. Brussels set up the expert bodies that will support AI Act enforcement. Semble raised £30m to scale a platform already embedded in UK care delivery. Sanofi brought Biogen into a…
Europe Life Sciences Weekly Signal #39 Acquiring Is Not Operating
Week of 25–31 May 2026 Life sciences organisations have never had more ways to acquire capability. They can buy pipelines, license products, enter new geographies through partnerships, deploy increasingly sophisticated AI platforms, or secure access to new markets through regulatory approvals. Capital remains available for the right assets, technology has become easier to access, and…
Get the Weekly Life Sciences Signal
Funding, regulation, AI, and strategic moves shaping life sciences in Europe in one sharp weekly read.
Strategic Perspectives on European Life Sciences
Life Sciences Market Intelligence
Funding, valuations, and strategic moves.
Commercialization & Go-to-Market
AI & Digital Health
About
Disrupting.healthcare is an independent publication focused on how commercial transformation actually happens in life sciences.
Operating models, market execution, AI, regulation, omnichannel and the European reality between global strategy and local adoption.
Piotr Wrzosinski, author and owner of disrupting.healthcare, is a life sciences commercial transformation leader with 20+ years of experience across pharma, MedTech, and consulting.